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An exploration of B2B social media practices in an 
era of digital transformation: The case of the 
pharmaceutical industry in Thailand 
  
Research suggests that humans’ experiences have been significantly 
impacted by the digitisation of communication technologies (Castell, 
2001). In this digital context, marketing practices in the B2B sector 
have shifted towards leveraging new technologies (Goggin, 2012) and 
new platforms such as social media. While some studies support the 
view that digitalisation processes have largely produced positive 
impacts, in turn creating marketing opportunities especially in 
emerging growing markets such as Thailand (Ansari and Phillips, 
2011; Gross, 2014); others point to the associated tensions that arise 
from that particular digital environment where technology demands 
challenge firms’ traditional frames of reference, stability and 
resources, thus threatening current strategies (Andriessen et al, 2011; 
Santos and Eisenhardt, 2009). Tension is defined as “clash of ideas or 
principles or actions and… the discomfort that may arise as a result” 
(Stohl et al.; 2001 pp.353, 354). As such, leveraging the power of 
social media in B2B (Pharmaceutical sector) is somehow under 
investigated especially in the context where strong legal constraints 
are present (Ventrataram and Nagatode, 2014; Whalen, 2012; Liu, 
2011). The aim of this study is to explore how and to what extent 
pharmaceutical stakeholders (firm, physician and pharmacist) are 
starting to leverage the power of social media communication. Sale 
force management and social media literature is utilized together with 
literature on communication and innovation management in B2B. 
Findings from 23 in depth interviews (6 physicians, 7 pharmacists and 
10 managers from a leading global pharmaceutical firm) are analysed. 
Themes such as content acceptance, self-efficacy, control, managerial 
tensions, technical issue (security and privacy) and legislation impact 
are found to be relevant. In addition, cultural factors appear to also 
mediate engagement by stakeholders. Theoretical implication of social 
media communication in B2B sector under strong and evolving 
legislative conditions are discussed together with the emerging 
managerial implications for the pharmaceutical industry of digital 
transformation in an era of accelerated culture. 
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Extended abstract 
 
In B2B both technology influence and relationships with broader marketing and management 
research has a long history (Bidgoli, 2010). Regarding the sales discipline in particular, the 
role of technology, from early non-networked main frame to personal ubiquitous laptops and 
today’s mobile Smartphones/tablets, is well documented (Comer, 1975; Anderson, 1996; 
Moncrief et al., 2015). Relating the multifaceted relationships between Information 
Communication Technologies (ICT) and sales personnel, over the years, a large literature has 
emerged ranging from customer relationship management to sales force automation (Bush et 
al, 2005). Today, the latest marketing channel, social media, is being explored to enhance 
firms’ social interactions with global value chains, which promotes sharing, telling, and 
overall interactive two way communication within the supply chain (Michaelidou et al, 2011; 
Vuori 2012).  
As portrayed by Kaplan et al., (2010), social media is a combination of internet 
applications in a Web 2.0 environment, enabling and fostering relationships and exchange of 
user generated content among various stakeholders. Social media tools (software and 
hardware) assist internal communications while engaging existing and potential value chain 
partners (Treem et al, 2012). Social media applications are found to empower partners, foster 
innovation, cut costs, reduce delays and improve overall firm performance (Agnihotri et al., 
2012; Andzulis et al., 2012). Numerous studies exist investigating adaptation of social media 
in B2B (Shih 2009; Bulte et al., 2007), competitive advantages for smaller businesses (Copp 
et al., 2001), establishment of long term relationships (Schultz et al, 2012), resource allocation 
(Kietzmann et al., 2011) and evaluation of unfamiliarity with technology and perceived lack 
of control (Buehrer et al, 2005, Kho, 2008) to name a few.  
Yet, reports show that overall B2B firms are slower to adopt these technologies 
(Agnihotri, et al., 2012). White Horse, (2010), a survey which specifically looks into the B2B 
market, reported that the reasons to justify the situation include lack of skills (generational 
argument); lack of access to ICT by all partners; and misfit with current management 
practices (lack of control). Also among these reasons are; firm, often vertical, organizational 
structure; the fact that many firms are only consumer focused or ROI-driven (unproven 
channel); a perception that decisions are more rational in B2B as opposed to B2C where they 
can be emotional (no needs in the field); and B2B marketing is less brand driven with few 
known players (White Horse, 2010). What is more, a clear gap exists in the literature 
regarding the specific case of ‘regulated’ industries. Regulated industries include for example, 
financial services, Tabaco and alcohol, pharmaceutical but also food preparation, chemicals, 
telecommunications, electricity, gas, water and oil (Garcia-Canal and Guillén, 2008). These 
industries are often regulated through in-country and cross-border regulators such as FDA and 
European Agency for the Evaluation of Medical Products. Their core concerns regarding 
social media include the licencing of products, pricing, misinformation, updates, promotions, 
and their trade including B2B and B2C deals (Elefant, 2011; Spain et al., 2001). In terms of 
cross-border trade, the limitations of international laws allow trade gaps for the regulated 
markets. Not surprisingly, when it comes to the regulation of online marketing of 
pharmaceutical products, regulators are more concerned about the B2C marketing than B2B 
marketing (Spain et al., 2001). The easy conduct of counterfeit transactions, illegal drugs 
trade, and misinformation over the online sales sites form some of the reasons of 
pharmaceutical regulations in B2C markets (Mackey, 2012).  
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Indeed, the pharmaceutical industry is often described as one of few large and global 
industries, that has yet to leverage digital marketing and social media in particular in sales 
management (Klue, 2009; Lerer and Piper, 2003). 
Aitken, the Executive Director of IMS Institute for 
Healthcare Informatics (2014), stated that in the 
B2C market half of the top 50 global 
pharmaceutical companies still ignore digital 
media when creating healthcare-related contents to 
engage the users. The IMS Health Social Media 
Engagement Index which reflects the overall 
usage of social media including Twitter, Facebook 
and YouTube by pharmaceutical companies on 
relevant topics about healthcare shows (Table 1) 
the clear lack of engagement even by the largest 
firms. In B2B, further concerns are present 
regarding the lack of standards in digital media 
usage (impact on ROI) together with unclear and 
impractical regulations associated with social 
media (potential litigation and legal impact) 
(Venkataram and Nagatode, 2014). Consequently, 
traditional platforms of communication are often 
preferred mostly requiring pharmaceutical value 
chain actors to interact with sales representatives 
via face-to-face to gain information on the latest 
research, or selected top selling drugs innovations 
(Britnell, 2011). 
 
For example, in the US, the Food and Drug Administration (FDA) (2014) has long 
been concerned with social media and digital marketing related applications. Thus, regularly 
publishes updated guidance for the pharmaceutical industry under the topic of “Fulfilling 
Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media 
for Prescription Human and Animal Drugs and Biologics” which covers mainly the B2C 
market, and over the counter drugs. Set of guidance principles and rules determine how “a 
firm is responsible for product promotional communications on sites that are owned, 
controlled, created, influenced, or operated by, or on behalf of, the firm”. These include any 
sites supported by pharmaceutical companies including social media sites. The US FDA 
(2014) also underlines that any product promotional communications of pharmaceutical firms 
must be submitted to FDA for approval prior to publishing on any marketing channel. In our 
case of Thailand, Hutagalung the Regional Director of US-ASEAN Business Council (2010) 
also confirmed that “All advertisements of pharmaceutical firms in Thailand must be pre-
approved by government officials before they are allowed to be dispatched and promoted”. 
Furthermore, Francer et.al., (2014) remarked that any nation that requires pharmaceutical 
rules and guidance in a new area such as digital marketing, must verify that provision of 
information is compatible with the International Federation of Pharmaceutical Manufacturers 
& Associations (IFPA) code which in the case of Thailand, is represented by the 
Pharmaceutical Research and Manufacturers Association (PReMA) of Thailand. For 
promotional media, PReMA of Thailand (2008) explained that “audio-visual materials 
including sound recordings, VCD, DVD-recordings, tape slide presentations, video-
recordings and sound or television broadcastings, etc., must comply with all relevant 
requirements of the Code and be restricted to an audience of healthcare professionals”.  
Table 10: Ranking by IMS Health Social 
Media Engagement Index 
IMS Health Social Media 
Engagement Index 
Score 
Johnson and Johnson 70 
GlaxoSmithKline (GSK) 25 
Novo Nordisk 23 
Pfizer 20 
Novartis 18 
Boehringer Ingelheim 18 
Bayer 16 
Merck & Co 13 
AstraZeneca 10 
UCB 9 
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These strict guidance and regulations create interesting conundrum regarding the 
opportunities and challenges offered by the social media channel and B2B sales management 
particularly for regulated sectors. First, social media postings do not foster pre-approval of 
content but real time communication making deployment and management complex 
(Michaelidou et al, 2011). Second, regulatory approval of material is often slow and 
incompatible with limitless discussion thread and limitless size for documentation and 
information. Third, web 2.0 encouraged the sharing of material such as videos and photos that 
are often presenting multi-faceted information, from numerous stakeholders including 
competitors in a single file, making it harder to be controlled and less likely to be approved. 
Fourth, social media encourages open, often anonymous, and speculative discussions 
presenting difficulties in a context driven by information based transactions. That is, where 
the information is false or includes biased presentation of evidence, or when some actors 
volunteer to be excluded from the conversation (intense competition), or access to proprietary 
data are common. Essentially, in many deals with government hospitals; thus, competitive 
bidding among suppliers is at play, rendering information on social media sensitive 
information, revealing factors, such as quality levels, timing of deliveries, inventory, and 
customization possibilities. Moreover, most firms do not have resources to investigate fully 
their customers’ priorities, create distinctive (local) offerings, or even map out paths to 
profitability. To be precise, buyer-biased exchanges that characterize B2Bs of today will not 
be able to achieve the required critical mass to achieve ROI (lack of standards).  Furthermore, 
other services may have to be developed to make the channel sustainable. Among these, stock 
planning, maintenance contracts, ICT training, or integrated multi-drug services (bundle of 
products) can be listed. Lastly, in the pharmaceutical sector, in particular, trust in information 
provided has been low due to mass reported court cases involving drug side effects, poor 
information disclosure and unethical research funding practices to name a few 
(Braithwaite,1993). 
Yet, as Schneider, the Executive VP of Greystone.net, stated "It is impossible to 
ignore the effect that social media is having on the Internet in general, and on hospitals and 
health systems specifically" (Commins, 2010). Still, Greene and Kesselheim (2010) quickly 
underline that it is arduous to provide an effective balance between risk and description of 
medicine with character limit on social media. For instance, Twitter allows only 140 
characters per tweet. It is too short for a post of indication and important information. 
Nevertheless in the case of emerging market and middle income countries (MIC) in particular, 
Andrew Witty (2011), Chief Executive of GSK, stated “that new customers in emerging 
markets were targeted, there was a high demand in healthcare products but many people in the 
MICs still could not access suitable treatments, medication and information about novelties”. 
Clearly further access to information is required by health professional that ought to lead to 
better and cheaper healthcare overall. If the pharmaceutical marketers could leverage the 
opportunities offered by the new digital channel, it could support pharmaceutical companies’ 
sales, allowing them to be more efficient so as to engage with a greater variety of 
stakeholders. This leverage would be the product of pharmaceutical consortiums, similar to 
R&D activities (Sakakibara, 2002). 
The aim of this study is; thus, to provide insights into how and to what extent a set of 
pharmaceutical stakeholders (firm, physician and pharmacist) are starting to characterize and 
leverage the complexity of B2B social media marketing in the sector. We first address these 
questions by drawing on the literature on sales management and social media with literature 
on communication and innovation management in B2B. We then use a case study of a large 
global firm in Thailand through 23 in depth interviews to illustrate the issues. 
This study makes two contributions to discussions of digital transformation and B2B 
social media in highly regulated sector. First, this study develops a greater understanding of 
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the significances and nuances of key characteristics such as content acceptance, self-efficacy, 
control, managerial tensions, technical issue (security and privacy) and legislation impact 
which allow stakeholders to manage competing logics and their shifting salience within 
pharmaceutical B2B social media development. Second, this study provides insights into the 
management of social media in regulated industries addressing a clear lack of research in the 
literature. In doing so, we provide a deeper understanding of the nature of how social media 
management by sales force is experienced particularly as a property of capability 
enhancement, and how competing logics of marketing communication coexist. This analysis 
extends our understanding beyond the more visible signs of instability and conflict, which 
might cause the termination of social media initiatives towards an understanding of the on-
going discomfort resulting from active endeavour. We then propose that social media 
management in regulated B2B industries could be developed leveraging frameworks based on 
consortium and co-opetion behaviours, a situation found in new market creation conditions 
(Toral et al., 2015). 
Digital transformation of the firm has been at the forefront of most manager agenda 
over the last decade (Van Belleghem, 2014). Social media growth as the key channel to 
communicate in real time using multiple formats reflecting the changing nature of the sales 
force management and the day to day roles attributed to sales force cannot be ignored any 
longer (Andzulis, Panagopoulos, and Rapp, 2012). The traditional assumptions put forward 
by the firm not to engage i.e. sales people using social media due mainly to generational gap 
(Robinson, Marshall, & Stamps, 2005), and that social media may be irrelevant to the field do 
not hold anymore. Indeed, under B2B conditions and within highly regulated industries, the 
lack of models and practices may level the generational field further than expected and call 
for integration with traditional tactics. Beyond the gadgetology of the various tools that could 
be leveraged by sales personnel, strategic thinking seem to be lacking with a certain lack of 
leadership to overcome the inertia of internal politics, leaving little directions for mangers. 
Still, following the traditional Walker, Churchill, and Ford’s (1979) model, Moncrief, 
Marshall and. Rudd (2015) clearly describe how sale force management functions, including 
selection, training supervision, compensation and deployment are affected by social media 
(see Table 2 p 50). In fact, today’s global competitive pressures require higher engagement 
with business partners, regular explanation and demonstration of expertise, understanding of 
partners’ diversity, dynamic change, and brand enthusiasm which encourages actions. These 
engagements are particularly crucial to increase firm and industrial efficiency, alignment of 
policies, standardization and flexibility of resources (Castro et al., 2003). But, they are not 
without the potential co-opetitive tensions which challenge these engagements (Kankanhalli, 
et al., 2006). Moreover, nothing is said about the content creation and management of the 
information and knowledge that then can be discussed, shared and commented upon, a central 
criterion for highly regulated industries as pre-approval is required. In essence, the literature 
has up to now concentrated mainly on the mechanics of applying social media in B2B sales 
force management often emphasizing the new relationship with consumer i.e. B2C. 
Findings from 23 in depth interviews (6 physicians, 7 pharmacists and 10 managers 
from a leading global pharmaceutical firm) are analysed. Themes such as content acceptance, 
self-efficacy, control, managerial tensions, technical issue (security and privacy) and 
legislation impact are found to be relevant. In addition, cultural factors appear to also 
facilitate engagement by stakeholders. Theoretical implication of social media communication 
in B2B sector under strong and evolving legislative conditions are discussed together with the 
emerging managerial implications for the pharmaceutical industry of digital transformation in 
an era of accelerated culture. Lastly, a framework based on consortium co-opetition literature 
in new market development is proposed as a potential solution. 
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